Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.
Int Immunopharmacol. 2018 Aug;61:178-184. doi: 10.1016/j.intimp.2018.05.020. Epub 2018 Jun 7.
Int Immunopharmacol. 2018.
PMID: 29885638
Review.